Radiotherapy Induced Oral Mucositis Treatment Market Forecasts to 2030 – Global Analysis By Treatment Type (Topical Agents, Systemic Agents and Medical Devices), Radiotherapy Type, Severity of Oral Mucositis, End User and By Geography

Radiotherapy Induced Oral Mucositis Treatment Market Forecasts to 2030 – Global Analysis By Treatment Type (Topical Agents, Systemic Agents and Medical Devices), Radiotherapy Type, Severity of Oral Mucositis, End User and By Geography

According to Stratistics MRC, the Global Radiotherapy Induced Oral Mucositis Treatment Market is accounted for $5.15 billion in 2023 and is expected to reach $7.44 billion by 2030 growing at a CAGR of 5.4% during the forecast period. Radiotherapy-induced oral mucositis (RIOM) treatment typically involves a multifaceted approach aimed at managing symptoms and promoting healing. These may include oral hygiene measures like gentle brushing and rinsing with saline solution or prescribed mouthwashes to reduce microbial growth and alleviate pain. Radiotherapy-induced oral mucositis treatment plays a crucial role in improving patient outcomes and enhancing the tolerability of cancer therapy.

According to the World Health Organization (WHO), cancer is the second leading cause of death globally, with an estimated 9.6 million deaths in 2018 and over 400,000 people in the US are estimated to receive an oral mucositis diagnosis each year.

Market Dynamics:

Driver:

Expanding geriatric population

With age, individuals become more susceptible to oral complications from radiotherapy, exacerbating the need for targeted solutions. RIOM can significantly impact the quality of life for elderly patients undergoing cancer treatment. As this demographic continues to grow, there is a pressing need for innovative therapies that alleviate RIOM symptoms, such as pain and difficulty in eating and speaking, thus highlighting the importance of advancing treatments tailored to meet the needs of older patients, thereby, driving the market growth.

Restraint:

Limited awareness

Limited awareness about the management and prevention of RIOM can hinder effective treatment. Patients may not recognize early symptoms or understand the importance of preventive measures, leading to delayed intervention and exacerbation of symptoms. Without proper education and awareness, patients may not adhere to prescribed treatments or lifestyle modifications, further complicating the management of RIOM and potentially compromising treatment outcomes.

Opportunity:

Rising healthcare expenditure

Rising healthcare expenditure drives demand for effective treatments like RIOM treatment due to its prevalence in cancer patients undergoing radiation therapy. With healthcare budgets expanding, there's greater investment in innovative therapies addressing RIOM's debilitating effects, such as pain and difficulty eating. This increased funding facilitates research into novel treatment modalities. Consequently, healthcare providers are more inclined to adopt these solutions, bolstering the market for RIOM treatment options and driving further advancements in patient care within oncology settings.

Threat:

Inadequate healthcare infrastructure

Inadequate healthcare infrastructure poses significant challenges to effective treatment of RIOM. Limited access to specialized healthcare facilities and trained personnel can delay diagnosis and intervention. Insufficient resources may lead to shortages of essential medications and equipment necessary for managing RIOM symptoms, such as pain relievers and oral hygiene products. Additionally, inadequate infrastructure may hinder patient education and follow-up care, reducing the overall quality of treatment outcomes.

Covid-19 Impact

The covid-19 pandemic has significantly impacted the RIOM treatment market. Delays in cancer diagnoses and treatments, along with disruptions in healthcare services, have led to reduced patient volumes and procedural postponements, affecting the demand for RIOM treatments. Additionally, stringent infection control measures and resource reallocations within healthcare facilities have further impeded market growth. However, advancements in telemedicine and homecare solutions have emerged as potential strategies to mitigate these challenges, facilitating continued access to RIOM treatment options amidst the pandemic.

The brachytherapy segment is expected to be the largest during the forecast period

The brachytherapy segment is estimated to have a lucrative growth. Brachytherapy, a form of radiotherapy, is emerging as a promising treatment for radiotherapy induced oral mucositis. Brachytherapy delivers targeted radiation directly to the affected area, minimizing damage to surrounding healthy tissue. As a result, it shows potential in reducing the severity of RIOM symptoms and improving patient quality of life. Its efficacy and precision make it a significant contender in the evolving landscape of RIOM treatment modalities.

The cancer treatment centers segment is expected to have the highest CAGR during the forecast period

The cancer treatment centers segment is anticipated to witness the highest CAGR growth during the forecast period. Radiotherapy-induced oral mucositis treatment in cancer treatment centers typically involves a multifaceted approach aimed at managing pain, preventing infection, and promoting healing. Additionally, advanced techniques like low-level laser therapy or cryotherapy may be employed to reduce inflammation and promote tissue repair. The goal is to mitigate symptoms, maintain oral hygiene, and improve the patient's quality of life during cancer treatment.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to rising cancer incidence and advancements in radiotherapy techniques. Moreover, supportive government initiatives and improving healthcare infrastructure are fostering market development. Key players are focusing on strategic collaborations and product innovations to gain a competitive edge. Overall, the Asia Pacific radiotherapy induced oral mucositis treatment market is poised for continuous growth in the foreseeable future.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period, owing to high prevalence of cancer, advanced healthcare infrastructure, and technological advancements. The market sees significant investments in innovative radiotherapy technologies in the region. Moreover, favourable reimbursement policies and a strong presence of key market players contribute to market growth. Increasing awareness about the efficacy of radiotherapy as a treatment option for various cancers, further fuels demand.

Key players in the market

Some of the key players profiled in the Radiotherapy Induced Oral Mucositis Treatment Market include The 3M Company, GlaxoSmithKline PLC, Sun Pharmaceutical Industries Limited, Fagron Group BV, Pfizer Inc., Merck & Co. Inc., Eusa Pharma, Valeant Pharmaceuticals International Inc., Eisai Corporation, Amgen Inc., Galera Therapeutics Inc., EpicentRx, Soligenix Inc., Cellceutix Corporation and GI Solutions Group.

Key Developments:

In March 2023, EpicentRx announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to RRx-001, a direct NLRP3 inhibitor and Nrf2 upregulator with anti-inflammatory and antioxidant properties, for the prevention/attenuation of severe oral mucositis in chemotherapy and radiation-treated head & neck cancer patients.

In February 2023, Galera Therapeutics announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and granted priority review to the New Drug Application (NDA) for avasopasem manganese for radiotherapy (RT)-induced severe oral mucositis (SOM) in patients with head and neck cancer (HNC) undergoing standard-of-care treatment.

Treatment Types Covered:
• Topical Agents
• Systemic Agents
• Medical Devices

Radiotherapy Types Covered:
• External Beam Radiation Therapy (EBRT)
• Intensity-Modulated Radiation Therapy (IMRT)
• Brachytherapy
• Proton Therapy
• Stereotactic Radiosurgery (SRS)
• Other Radiotherapy Types

Severity of Oral Mucositis Covered:
• Mild
• Moderate
• Severe
• Life-threatening

End Users Covered:
• Hospitals
• Cancer Treatment Centers
• Ambulatory Surgical Centers
• Research Institutes
• Other End Users

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements